Skip to main content
Premium Trial:

Request an Annual Quote

Affibody to Develop, Produce Protein Ligands for Agilent s Sample Prep Products

NEW YORK, Aug. 23 (GenomeWeb News) - Affibody of Stockholm, Sweden, will develop protein affinity ligands for Agilent Technologies' protein sample preparation products, the companies said today.

 

Under the agreement, Affibody will design and develop affinity capture ligands for certain proteins specified by Agilent, using its Affibody technology. Agilent plans to incorporate these reagents into its protein removal technology for sample preparation. Eventually, Affibody will supply Agilent with production quantities of the reagents.

 

Affibody molecules are highly specific affinity proteins that mimic monoclonal antibodies. They are produced by combinatorial protein engineering applied on a proprietary scaffold.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.